Avagacestat
- Generic Name
- Avagacestat
- Drug Type
- Small Molecule
- Chemical Formula
- C20H17ClF4N4O4S
- CAS Number
- 1146699-66-2
- Unique Ingredient Identifier
- TQ44WWY45Q
- Background
Avagacestat has been investigated for the basic science and treatment of Alzheimer Disease.
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2011-02-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT01079819
- Locations
- 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States
🇺🇸California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸Iberica Clinical Research Center, Eatontown, New Jersey, United States
Multiple Dose Japanese Bridging Study
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT01057030
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
Drug-Drug Interaction Study With Aricept® (Donepezil)
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT01042314
- Locations
- 🇺🇸
Parexel International - Baltimore Epcu, Baltimore, Maryland, United States
Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT01039194
- Locations
- 🇺🇸
Parexel International - Baltimore Epcu, Baltimore, Maryland, United States
Drug-Drug Interaction Study With Rifampin
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT01002079
- Locations
- 🇮🇳
Local Institution, Bangalore, India
Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 62
- Registration Number
- NCT00979316
- Locations
- 🇺🇸
Mds Pharma Services (Us), Inc, Tempe, Arizona, United States
Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT00901498
- Locations
- 🇺🇸
Mds Pharma Services (Us) Inc., Neptune, New Jersey, United States
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 263
- Registration Number
- NCT00890890
- Locations
- 🇺🇸
Pivotal Research Centers, Peoria, Arizona, United States
🇺🇸Nyu Langone Medical Center, New York, New York, United States
🇺🇸Yale University School Of Medicine, New Haven, Connecticut, United States
Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT00860275
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT00828646
- Locations
- 🇯🇵
Local Institution, Yokohama, Kanagawa, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.